Skip to main
AMGN
AMGN logo

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 58%
Sell 8%
Strong Sell 0%

Bulls say

Amgen has demonstrated strong revenue growth, with a 40% increase in sales during the third quarter of 2025 compared to the same period in 2024, driven by double-digit growth across 16 of its products, including notable performers such as Repatha and Tezspire. Additionally, the company's investment in research and development is set to enhance its innovative pipeline, with guidance indicating a growth rate exceeding 20% in R&D spending for 2025 compared to the prior year. This combination of robust sales expansion and a commitment to advancing its product offerings supports a positive outlook for Amgen's financial future.

Bears say

Amgen is projected to experience minimal revenue growth of approximately 1% in 2026 compared to 2025, primarily due to significant anticipated sales declines of about 28% for Prolia and 39% for Xgeva. Furthermore, management indicated that growth in research and development spending will be less pronounced than in previous years, which may hinder the company's ability to innovate and offset losses from declining drug sales. These factors contribute to a concerning outlook on Amgen's overall financial health and future revenue streams.

Amgen (AMGN) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 58% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 12 analysts, Amgen (AMGN) has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $314.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $314.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.